Olanzapine and fluoxetine.svg
Combination of
OlanzapineAtypical antipsychotic
FluoxetineSelective serotonin reuptake inhibitor
Clinical data
Trade namesSymbyax, Cinol Forte, Olapin Forte, others
AHFS/Drugs.comProfessional Drug Facts
License data
  • AU: C
Routes of
By mouth
ATC code
Legal status
Legal status
CAS Number
 ☒NcheckY (what is this?)  (verify)

Olanzapine/fluoxetine (trade name Symbyax, created by Eli Lilly and Company) is a fixed-dose combination medication containing olanzapine (Zyprexa), an atypical antipsychotic, and fluoxetine (Prozac), a selective serotonin reuptake inhibitor (SSRI). Olanzapine/fluoxetine is primarily used to treat the depressive episodes of bipolar I disorder[2] as well as treatment-resistant depression.[1][3]

Medical uses

Olanzapine/fluoxetine was approved by the U.S. Food and Drug Administration (FDA) to treat the depressive episodes of bipolar I disorder in 2003.[1] In 2009, it was granted approval for the treatment of treatment-resistant depression.[4]

Olanzapine/fluoxetine, or other antidepressant/antipsychotic combinations, are sometimes prescribed off-label for anxiety disorders,[5] eating disorders,[6] obsessive–compulsive disorder (OCD),[7] and posttraumatic stress disorder (PTSD).[8]

Side effects

Possible side effects of olanzapine/fluoxetine include all those of the two component drugs: olanzapine (side effects) and fluoxetine (side effects). Common side effects include suicidal thoughts, increased appetite, weight gain, drowsiness, fatigue, dry mouth, swelling, tremor, blurred vision, and difficulty concentrating.[1]

Olanzapine/fluoxetine could produce a severe allergic reaction and should not be used if the patient has previously experienced an allergic reaction to either fluoxetine or olanzapine.[9]

Olanzapine is correlated with an increase in blood sugar. Patients with diabetes, or those at risk for developing it, require careful monitoring.[9]

In rare cases, olanzapine/fluoxetine may cause neuroleptic malignant syndrome.[1]

Like other SSRIs, olanzapine/fluoxetine carries a boxed warning stating that it could increase the risk of suicidal thoughts and behaviors in patients aged 24 and under. The warning also states that olanzapine/fluoxetine may increase the risk of death in elderly patients with dementia-related psychosis.[1]

See also


  1. ^ a b c d e f "Symbyax- olanzapine and fluoxetine hydrochloride capsule". DailyMed. 21 April 2020. Retrieved 30 September 2020.
  2. ^ "Tratamento medicamentoso dos transtornos bipolares - Transtornos psiquiátricos". Manuais MSD edição para profissionais (in Brazilian Portuguese). Retrieved 2022-10-02.
  3. ^ Benazzi, Franco; Berk, Michael; Frye, Mark A.; Wang, Wei; Barraco, Alessandra; Tohen, Mauricio (2009). "Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis". The Journal of Clinical Psychiatry. 70 (10): 1424–1431. doi:10.4088/JCP.08m04772gre. ISSN 1555-2101. PMID 19906346.
  4. ^ Grohol, J. "FDA Approves Symbyax for Treatment Resistant Depression". Psych Central Blog.
  5. ^ McIntyre R, Katzman M (2003). "The role of atypical antipsychotics in bipolar depression and anxiety disorders". Bipolar Disorders. 5 Suppl 2: 20–35. doi:10.1111/j.1399-2406.2003.00061.x. PMID 14700010.
  6. ^ Pederson KJ, Roerig JL, Mitchell JE (2003). "Towards the pharmacotherapy of eating disorders". Expert Opin. Pharmacother. 4 (10): 1659–78. doi:10.1517/14656566.4.10.1659. PMID 14521477. S2CID 38506292.
  7. ^ Koran LM, Ringold AL, Elliott MA (2000). "Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder". J Clin Psychiatry. 61 (7): 514–7. doi:10.4088/JCP.v61n0709. PMID 10937610.
  8. ^ Stein MB, Kline NA, Matloff JL (2003). "Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study". Am J Psychiatry. 159 (10): 1777–9. doi:10.1176/appi.ajp.159.10.1777. PMID 12359687.
  9. ^ a b Drugs.com https://www.drugs.com/pdr/symbyax.html